EC Number   |
Title |
Organism |
|---|
   3.4.21.98 | Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro |
Hepatitis C virus genotype 1b |
| 3.4.21.98 | Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease |
Hepacivirus C |
| 3.4.21.98 | Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857) A component of Vosevi |
Hepacivirus C |
| 3.4.21.98 | Evaluating the inhibitory effect of eight compounds from Daphne papyracea against the NS3/4A protease of hepatitis C virus |
Hepacivirus C |
| 3.4.21.98 | Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection |
Hepacivirus C |
| 3.4.21.98 | Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3 |
Hepatitis C virus genotype 2a |
| 3.4.21.98 | Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a |
Hepatitis C virus genotype 4a |
| 3.4.21.98 | Resistance outside the substrate envelope hepatitis C NS3/4A protease inhibitors |
Hepatitis C virus genotype 1b |
| 3.4.21.98 | Sequence analysis of hepatitis C virus nonstructural protein 3-4A serine protease and prediction of conserved B and T cell epitopes |
Hepacivirus C |
| 3.4.21.98 | Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus |
Hepatitis C virus genotype 1b |
